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countries. However, little is known about the epidemiology
of chronic kidney disease (CKD) outcomes. Here we describe
progression and mortality risk of patients with CKD but not
on renal replacement therapy at outpatient nephrology
clinics across Europe using individual data from nine CKD
cohorts participating in the European CKD Burden
Consortium. A joint model assessed the mean change in
estimated glomerular ﬁltration rate (eGFR) andmortality risk
simultaneously, thereby accounting for mortality risk when
estimating eGFR decline and vice versa, while also correcting
for themeasurement error in eGFR. Results were adjusted for
important risk factors (baseline eGFR, age, sex, albuminuria,
primary renal disease, diabetes, hypertension, obesity and
smoking) in 27,771 patients from ﬁve countries. The
adjusted mean annual eGFR decline varied from 0.77 (95%
conﬁdence interval 0.45, 1.08)ml/min/1.73m2 in the Belgium
cohort to 2.43 (2.11, 2.75) ml/min/1.73m2 in the Spanish
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1432mortality hazard ratio varied from 0.22 (0.11, 0.43) in the
London LACKABO cohort to 1.30 (1.13, 1.49) in the English
CRISIS cohort. These results suggest that the eGFR decline
showed minor variation but mortality showed the most
variation. Thus, different health care organization systems
are potentially associated with differences in outcome of
patients with CKD within Europe. These results can be used
by policy makers to plan resources on a regional, national
and European level.
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C hronic kidney disease (CKD) is one of the fastestgrowing causes of death worldwide.1 In stark contrast isthe lack of novel treatment options for the manage-
ment of CKD.2 Current predialysis care can slow the pro-
gression in patients with CKD and reduce mortality in ESRD
patients.3 In addition, national health care system character-
istics may inﬂuence outcomes in patients with CKD.4
Describing outcomes in CKD patients across regions and
countries may identify regions with overall slow CKDKidney International (2018) 93, 1432–1441
K Brück et al.: Progression and mortality in CKD c l i n i ca l i nves t iga t ionprogression and/or low rates of mortality. Such a comparison
may help to identify health care system characteristics that are
associated with improved population health. Moreover, infor-
mation regarding the decline of mean estimated glomerular
ﬁltration rate (eGFR) over time can be used by policy makers to
plan resources at the regional, national, and European level.
Up to the present, little is known about the epidemiology of
CKD progression. Studies from individual countries describing
CKD progression in referred CKD patients have reported de-
clines in the rates of eGFR varying from 0.35 to 5.16 ml/min
per 1.73 m2 per year.5,6 Next to differences in the way pro-
gression is being expressed, comparisons of these studies is
complicated by differences in baseline eGFR, albuminuria,
primary renal disease (PRD), and presence of comorbidities, all
factors that independently may inﬂuence the rate of CKD
progression.7 Importantly, as the rate of change in eGFR in-
ﬂuences mortality risk,8 mortality risk needs to be taken into
account when describing eGFR change in CKD patients.
A relatively new statistical method, which enables simul-
taneous analysis of longitudinal and survival data, is the joint
model.9,10 The main advantage of this model, in the context
of CKD progression, is its ability to correct for the mea-
surement error in repeated eGFRs.10,11 Another advantage is
that it accounts for mortality risk when estimating GFR
decline.9,12 Despite these clear advantages for studies inves-
tigating outcomes in CKD patients, joint models are currently
underused within the nephrology research.11,13
The objective of this study was to describe CKD progres-
sion and mortality outcomes in patients attending outpatient
nephrology clinics. We used individual patient data from 9
CKD cohorts in 5 European countries taking part in the
European CKD Burden Consortium.14,15 Using a joint model,
we combined a linear mixed model to estimate mean annual
eGFR changes and a Weibull survival model to estimate all-
cause mortality risk. Additionally, we determined mean
annual eGFR changes for subgroups based on age, sex, and
the presence of diabetes mellitus.
RESULTS
Study characteristics
We obtained data from 9 cohort studies,16–22 followed in 5
European countries, including a total of 27,771 CKD patients
not on renal replacement therapy (RRT), of which 25,702
patients (93%) had a baseline eGFR below 60 ml/min per 1.73
m2. Of these patients, 18,126 had at least 2 creatinine mea-
surements and were included in the main analysis. Inclusion
and exclusion criteria for the cohorts are listed in Table 1.
One cohort (Complesso Integrato Columbus [CIC]) did not
have any exclusion criteria, 3 cohorts (Prevention of Renal
Insufﬁciency Progression [PIRP], Chronic Renal Insufﬁciency
Standards Implementation Study [CRISIS], London Arterial
Calciﬁcation, Kidney and Bone Outcomes [LACKABO])
solely excluded patients with acute kidney injury or with RRT
at ﬁrst presentation, and the remaining cohorts had addi-
tional exclusion criteria in place. Table 1 additionally shows
the type of access to nephrology care by cohort. Four cohortsKidney International (2018) 93, 1432–1441applied an open access system (i.e., patients could visit a
nephrologist without a referral from their general practi-
tioner). In the other 5 cohorts, patients required a referral
from their general practitioner prior to visiting the nephrol-
ogist (i.e., gatekeeper system).
Data extraction
All cohorts provided data for serum creatinine concentration,
age, and sex. Eight cohorts provided data for the presence of
comorbidities, baseline albuminuria, and PRD. Of the pa-
tients included in the main analysis, 34% had data available
for either albuminuria or proteinuria. Tables 2 and 3 show
baseline characteristics, and the availability of follow-up
measurements of patients included in the main analysis
(i.e., CKD stages 3 to 5 and $2 creatinine measurements).
Supplementary Table S1 shows the characteristics of all
included patients compared to those with only 1 creatinine
measurement. Eight studies (89% of included studies) used
isotope dilution mass spectrometry (IDMS) standardized
creatinine measurements, of which 1 study used IDMS
standardized creatinine methods in 79% of included patients.
CKD outcomes
We assessed CKD progression by using a joint model,
simultaneously analyzing repeated measures of eGFR and
mortality risk. As such, mortality risk was taken into account
for the calculation of the mean annual eGFR decline, and
conversely, eGFR decline was taken into account for calcu-
lating the mortality risk. Both crude results and results
adjusted for baseline eGFR, age, sex, PRD, diabetes mellitus,
hypertension, obesity, and smoking are presented. Adjust-
ment for the presence of albuminuria and angiotensin-
receptor blockers (ARBs) and angiotensin-converting
enzyme inhibitors (ACEi’s) are presented in the
Supplementary Tables S2, S3, S4, and S5.
Survival analysis
Figure 1 and Table 4 show the crude and adjusted mortality
hazard ratios (HR) and their 95% conﬁdence intervals (95%
CI). The PIRP cohort served as the reference, based on
population size. The crude HR varied from 0.08 (95% CI,
0.04 to 0.16) in the English LACKABO cohort to 1.0 in the
reference population. The adjusted HR varied from 0.22 (95%
CI, 0.11 to 0.43) in the LACKABO cohort to 1.30 (95% CI,
1.13 to 1.49) in the CRISIS cohort. Supplementary Table S2
presents the HR additionally adjusted for use of ACEi and
ARB, indicating the impact of ACEi and ARB use in the causal
pathway between cohort and CKD outcome. This HR ranged
from 0.21 (95% CI, 0.11 to 0.41) in the LACKABO cohort to
1.11 (95% CI, 0.96 to 1.27) in the CRISIS cohort.
eGFR decline
Figure 1 and Table 5 show the crude and adjusted mean
annual eGFR decline by study including the 95% CI. The
crude mean eGFR decline varied from 0.30 (95% CI, þ0.03 to
0.62 [þeGFR indicates increase instead of decline]) ml/min
per 1.73 m2 per year in the Italian CIC cohort to 2.36 (95%1433
Table 1 | Inclusion and exclusion criteria according to study and access to specialist nephrology care
Study Country Region N Inclusion criteria Exclusion criteria Inclusion period
Access to
nephrologist
Belgium Ghent 557 All patients aged $18 yr
Willing to participate in biobanking
Recent AKI (<3 mo)
Recent acute CV event (<3 mo)
Infection
2008–2012 Open access
Cyprus Nicosia 104 CKD patients ($3 mo) Malignancy
Inﬂammation (<3 mo)
Major CV event (i.e., stroke/MI/
acute IHD) (<3 mo)
2012–2013 Open access
CIC Italy Rome 3008 All consecutive patients with $1
creatinine
measurements
None 2001–2015 Open access
MAURO Italy Multiplea 759 Age 18–75 yr
$2  creatinine >1.5 and <4.0 mg/dl
(men) or >1.3 and <3.5 mg/dl
(women)
or albuminuria >30 mg/24 h
$ 2 consecutive visits
AKI or rapidly evolving renal
disease;
transplant, pregnancy, cancer or
disease in a terminal phase
2005–2008 Open access
PIRP Italy Emilia
Romagna
18,244 All consecutive patients referred to
nephrologist by primary care
physicians
Subjects with RRT or AKI 2005–2015 Gatekeeper system
TABLE Italy Multipleb 1184 All consecutive patients with
eGFR<60 ml/min per 1.73 m2 (>3
mos)
Patients with acute kidney injury
(<6 mo before ﬁrst visit)
Patients with ﬁrst visit < 1 year
2000–2005 Gatekeeper system
PECERA Spain Valencia 995 CKD stage 4–5 not receiving dialysis
Life expectancy >1 yr
Informed consent
Kidney transplant, AKI, wasting
disease, malignancy,
incapacitating disease, or
active infection/inﬂammation
2006–2009 Gatekeeper system
CRISIS UK Manchester 2649 10 < eGFR #60 ml/min per 1.73 m2
Able to give written consent
AKI
Previous RRT
2002–2013 Gatekeeper system
LACKABO UK London 271 serum creatinine >150 mmol/l (men)
or >130 mmol/l (women)
Able to give consent
Subjects with RRT or AKI 2006–2008 Gatekeeper system
AKI, acute kidney injury; CIC, Complesso Integrato Columbus; CKD, chronic kidney disease; CRISIS, Chronic Renal Insufﬁciency Standards Implementation Study; CV, car-
diovascular; eGFR, estimated glomerular ﬁltration rate; Gatekeeper, referral by general practitioner required; LACKABO, London Arterial Calciﬁcation, Kidney and Bone
Outcomes; MAURO, multiple intervention and audit in renal diseases to optimize care; MI, myocardial infarction; N, total number of patients included in study; Open access, no
referral by general practitioner required; PECERA, Proyecto de Estudio Colaborativo En pacientes con insuﬁciencia Renal Avanzada; PIRP, prevention of renal insufﬁciency
progression; RRT, renal replacement therapy; TABLE, target blood pressure levels in CKD.
aMAURO patients included in 21 centers: 17 in Calabria, 3 in Sicily, 1 in Puglia, and 1 in Sardinia.
bTABLE patients included in 25 centers: most of these centers were located in southern Italy, surrounding Naples and further south, 1 from Verona, 1 from Pisa, 1 from Chieti,
and 3 from Sicily.
c l i n i ca l i nves t iga t i on K Brück et al.: Progression and mortality in CKDCI, 2.04 to 2.68) ml/min per 1.73 m2 per year in the Spanish
PECERA cohort. The adjusted mean annual eGFR decline
varied from 0.77 (95% CI, 0.45,1.08) ml/min per 1.73m2 in
the Belgium cohort to 2.43 (95% CI, 2.11,2.75) ml/min per
1.73m2 in the PECERA cohort. Supplementary Table S3
shows the eGFR decline additionally adjusted for ACEi and
ARB use; this ranged from 1.19 (95% CI, 0.90 to 1.47) in the
Italian MAURO cohort to 2.45 (95% CI, 2.12 to 2.77) ml/min
per 1.73m2 in the PECERA cohort.
Table 6 presents the eGFR decline for the subgroups by age,
sex, and presence of diabetes mellitus. The age group analysis
showed faster eGFR decline in the younger aged group than in
patients 65 years of age and older in all cohorts, except for the
LACKABO cohort. In that cohort, there were no differences in
eGFR decline between the 2 age groups. Overall eGFR decline
was slower in females than in males. In patients with diabetes
mellitus, mean annual eGFR decline was faster than in
patients without diabetes mellitus in all cohorts.
We performed sensitivity analyses in 3 separate groups, for
which the mean annual eGFR decline, including 95% CI, are1434all presented in the Supplementary Tables S4, S5, and S6.
Supplementary Table S4 shows results for the patients with
available baseline albuminuria measurements. Importantly,
the correction for baseline albuminuria only slightly changed
the rate of eGFR decline. Supplementary Table S5 shows the
results for patients with at least 3 creatinine measurements. In
Supplementary Table S6, we present the eGFR decline by
cohort based on 9 separate models, in contrast to the main
analysis in which all cohorts were analyzed in 1 model.
Overall the results from the sensitivity subgroup analyses were
in line with results of the main analysis.
DISCUSSION
In this prospective cohort analysis including individual data
of 27,771 CKD patients from 5 European countries, outcomes
in CKD patients varied signiﬁcantly among European
outpatient nephrology studies, while taking into account the
effect of eGFR changes in mortality risk and vice versa. Var-
iations in CKD outcomes persisted despite adjustment for
factors associated with CKD progression, such as baselineKidney International (2018) 93, 1432–1441
Table 2 | Population characteristics by study
Countries Belgium Cyprus Italy Spain UK
Studies UZGhent Nicosia CIC MAURO PIRP TABLE PECERA CRISIS LACKABO
N 403 70 1420 719 1,1277 1,031 939 2,049 218
Median age yr (range) 69 (61–77) 72 (68–76) 74 (66–80) 65 (57–70) 74 (67–80) 69 (58–76) 73 (61–79) 67 (56–75) 61 (51–70)
% of Males 61.0 71.4 58.6 59.1 64.6 57.3 60.4 61.6 72.0
% with Diabetes 35.7 60.0 36.6 34.9 36.6 26.8 35.9 32.3 20.2
% of Missing DM 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.8 0.0
% with Hypertensiona 48.4 98.6 NA 94.4 97.8 97.1 91.4 95.9 83.9
% of Missing HT 0.0 0.0 100.0 0.0 0.0 0.0 0.0 0.0 0.0
% with Obesity 34.8 61.4 NA 31.9 24.0 25.7 30.9 NA 26.4
% with Missing BMI 0.2 0.0 100.0 0.3 0.0 0.0 0.1 100.0 7.8
Current smokers, % 11.9 24.3 NA 12.5 9.5 9.5 11.3 12.6 13.8
% of Ex–smokers 40.5 25.7 NA 37.1 41.7 22.9 34.0 53.4 30.7
% of Missing smokers 2.0 0.0 100.0 0.0 29.1 0.0 0.0 4.1 0.0
% using ACEi NA 48.6 NA 65.7 40.8 52.6 33.0 43.4 50.9
% using ARBs NA 75.7 NA 41.2 37.5 25.2 55.0 26.5 40.8
% Missing medication 100.0 0.0 100.0 5.6 0.0 0.0 0.0 0.9 0.0
% of PRD
Vascular 27.7 22.9 12.0 59.7 25.0 40.9 25.3 6.1
Diabetic nephropathy 19.5 60.0 8.0 12.0 14.6 13.5 17.2 12.6
Glomerulonephritis 10.5 10.0 8.0 4.6 12.6 6.7 16.7 14.5
Tubule-interstitial 9.2 4.3 7.7 5.8 10.8 10.6 20.3 6.5
Polycystic kidney 3.0 7.4 3.2 5.5 4.6 5.2 9.8
Congenital 6.7 0.6 1.2 0.0 0.5
Other 12.0 3.5 0.6 10.2 12.2 15.3 31.8
Unknown 11.5 2.9 52.9 12.9 21.2 11.4 18.2
Missing PRD data 0.5 0.0 100.0 0.4 0.0 0.0 0.0 0.1 1.8
BMI, body mass index; DM, diabetes mellitus; glomerulonephritis, glomerulonephritis þ membranous nephropathy þ IgA nephropathy; NA, not applicable; obesity, BMI >30
kg/m2; tubule-interstitial, pyelonephritis þ interstitial þ post renal; vascular, hypertensive þ renovascular.
Median is presented with interquartile range in brackets.
aHypertension in the UZGhent cohort is based on blood pressure alone.
K Brück et al.: Progression and mortality in CKD c l i n i ca l i nves t iga t ioneGFR, age, sex, presence of albuminuria, diabetes mellitus,
hypertension, obesity, smoking, PRD, and medication used.
The slowest adjusted eGFR decline was seen in the BelgianTable 3 | Population characteristics by study; kidney function/da
Countries Belgium Cyprus
Studies UZGhent Nicosia CIC MAU
Baseline eGFR in ml/min per 1.73m2
Mean (SD) CKD-EPI 37.7 (11.5) 41.2 (11.3) 33.8 (12.3) 33.6
% of Baseline eGFR categories
45–59 29.3 41.4 21.8 19
30–44 43.2 40.0 35.7 39
15–29 25.3 15.7 40.8 34
<15 2.2 2.9 1.8 5
% with Albuminuria data
Normoalbuminuria 51.3 39.1 NA 18
Microalbuminuria 22.7 33.3 NA 28
Macroalbuminuria 26.0 27.5 NA 53
Missing 4.7 1.4 100.0 9
Follow-up data
Median (quartile range)
creatinine measurements
16 (11–26) 4 (4–4) 3 (2–5) 7 (6
Median duration follow-up,
yr
5.7 (4.0–7.6) 3.0 (3.0–3.0) 0.5 (0.0–1.9) 3.0 (3.
Rate per 1,000 person yr at 1 year follow-up
Mortality rate 7.5 14.4 NA 9
RRT rate 2.50 0.00 NA 5
% Missing follow-up 7.4 2.9 NA 0
NA, not available; normoalbuminuria, albumin creatinine ratio (ACR)<30 mg/g or protei
ACR 30–300 mg/g; PCR 150–500 mg/g or proteinuria 150–500 mg/24 h; macroalbumin
Means are presented with SDs; medians are presented with interquartile ranges.
Kidney International (2018) 93, 1432–1441cohort. In addition, the mortality and initiation of RRT were
very low in this cohort, suggesting that Belgian CKD patients
had an excellent prognosis for both renal and overall survival.mage and follow-up data
Italy Spain UK
RO PIRP TABLE PECERA CRISIS LACKABO
(12.0) 30.2 (11.9) 29.8 (13.8) 19.2 (5.4) 29.0 (13.3) 33.5 (13.5)
.9 12.9 17.4 NA 15.2 24.3
.5 35.6 28.3 2.0 28.0 33.9
.9 41.5 38.1 72.9 40.9 33.0
.7 10.0 16.2 25.0 15.9 8.7
.3 41.0 22.2 14.1 37.8 22.3
.6 36.6 24.5 28.7 29.8 28.9
.1 22.4 53.2 57.2 32.4 48.8
.5 92.8 0.0 5.6 7.9 44.5
–7) 4 (2–7) 4 (2–5) 5 (3–5) 4 (2–5) 5 (3–10)
0–3.0) 2.4 (1.2–4.3) 4.2 (2.2–5.1) 2.5 (1.3–3.0) 3.2 (1.9–5.8) 5.2 (4.6–5.4)
.8 22.5 4.6 27.1 8.4 4.2
.6 33.5 63.3 159.4 53.7 8.4
.0 2.7 0.0 22.9 0.0 4.1
n creatinine ratio (PCR) <150 mg/g or proteinuria <150 mg/24 h; microalbuminuria:
uria: ACR> 300 mg/g; PCR >500 mg/g or proteinuria >500 mg/24 h.
1435
Figure 1 | Forest plot of adjusted mean annual eGFR decline in ml/min per 1.73 m2 and adjusted mortality hazard ratio (HR) by study.
The Italian PIRP cohort is the reference group. | ¼ adjusted for baseline eGFR, age, sex, PRD, comorbidities, and smoking (model 5); Ɵ ¼ only
adjusted for age and sex. The hazard ratio for the Italian CIC cohort is not shown because they did not provide data for follow-up status.
CI, conﬁdence interval; CIC, Complesso Integrato Columbus; CRISIS, Chronic Renal Insufﬁciency Standards Implementation Study; eGFR,
estimated glomerular ﬁltration rate; LACKABO, London Arterial Calciﬁcation, Kidney and Bone Outcomes; MAURO, multiple intervention and
audit in renal diseases to optimize care; PECERA, Proyecto de Estudio Colaborativo En pacientes con insuﬁciencia Renal Avanzada; PIRP,
prevention of renal insufﬁciency progression; PRD, primary renal disease; TABLE, target blood pressure levels in CKD.
c l i n i ca l i nves t iga t i on K Brück et al.: Progression and mortality in CKDThe fastest adjusted eGFR decline was seen in the Spanish
PECERA and the English LACKABO cohorts. The fast eGFR
decline in the LACKABO cohort was in line with the rate of
need for RRT and the low mortality in this cohort.
Previous studies have shown that younger age, male sex,
and presence of diabetes mellitus are associated with more
rapid CKD progression.7,23,24 We have been able to conﬁrm
these associations, even after adjustment for several important
predictors of CKD progression and mortality risk. This
consistent effect of established risk factors suggests that the
observed differences in CKD outcomes across CKD cohorts
are due to other factors than age, sex, and diabetic status.
Importantly, we are the ﬁrst to show that the association
between eGFR decline and these risk factors persists after
adjustment for mortality risk.
Inﬂuence of selection criteria
Although we aimed to include comparable CKD cohorts, the
exclusion criteria among the individual studies varied. ThisTable 4 | Hazard ratio (95% CI) for mortality, with PIRP cohort a
Country Belgium Cyprus Italy
Study Ghent Nicosia CIC MAURO PIRP
N 323 70 1,420 719 1,127
Model 1 0.20 (0.14–0.30) 0.52 (0.19–1.44) NA 0.30 (0.21–0.43) ref
Model 2 0.22 (0.15–0.32) 0.55 (0.20–1.52) NA 0.74 (0.52–1.07) ref
Model 3 <Events 0.41 (0.15–1.10) NA 0.73 (0.51–1.04) ref
Model 4 <Events 0.53 (0.19–1.45) NA 0.75 (0.52–1.07) ref
Model 5 <Events 0.55 (0.20–1.52) NA 0.76 (0.53–1.10) ref
CI, conﬁdence interval; eGFR, estimated glomerular ﬁltration rate; NA, not applicable; P
Model 1, crude (aadjusted for baseline eGFR by use of random intercept); Model 2, age an
(diabetes, hypertension and obesity); Model 6, 5 þ smoking.
1436could have resulted in the selection of healthier patients in
some studies compared to studies without additional exclu-
sion criteria.
The Italian CIC cohort was the only unselected cohort,
including all patients from the nephrology outpatient clinic.
Although this cohort showed the slowest crude eGFR decline,
we had insufﬁcient information to fully compare these results
with the other cohorts. Two cohorts, the Belgian and Cypriot
cohorts, excluded patients with recent cardiovascular events.
Given that cardiovascular death is the main cause of death in
patients with CKD,25 this selection may partly explain the low
mortality HR observed of, respectively, 0.22 (95% CI, 0.15 to
0.32) and 0.55 (95% CI, 0.20 to 1.52). The Italian cohorts
MAURO and TABLE excluded rapid loss in kidney function
and recent acute kidney injury, respectively. This may have
contributed to a relatively low mortality HR, as rapid eGFR
decline is associated with an increased mortality risk.8 The
Spanish PECERA cohort showed a relatively rapid eGFR
decline and high mortality and RRT initiation. This may ins reference group
Spain UK
TABLE PECERA CRISIS LACKABO
7 103,100 939 2,049 218
. 0.42 (0.35–0.50) 0.76 (0.63–0.93) 0.77 (0.70–0.85) 0.08 (0.04–0.16)
. 0.63 (0.52–0.75) 0.93 (0.76–1.14) 1.21 (1.09–1.34) 0.20 (0.10–0.38)
. 0.68 (0.57–0.82) 1.34 (1.12–1.61) 1.29 (1.17–1.43) 0.20 (0.10–0.39)
. 0.66 (0.55–0.80) 0.99 (0.82–1.21) 1.34 (1.18–1.52) 0.21 (0.11–0.42)
. 0.68 (0.57–0.82) 1.01 (0.82–1.24) 1.30 (1.13–1.49) 0.22 (0.11–0.43)
RD, primary renal disease; RRT, renal replacement therapy.
d sex adjusted; Model 3, 2 þ RRT start; Model 4, 3 þ PRD; Model 5, 4 þ comorbidities
Kidney International (2018) 93, 1432–1441
Table 5 | Mean annual eGFR decline (ml/min per 1.73 m2 (95% CI,) by study
Country Belgium Cyprus Italy Spain UK
Study Ghent Nicosia CIC MAURO PIRP TABLE PECERA CRISIS LACKABO
Model 1 0.76 (0.50–1.02) 1.86 (0.85–2.86) 0.30 (þ0.03– 0.62) 1.41 (1.14–1.67) 1.71 (1.62–1.79) 2.04 (1.78–2.29) 2.36 (2.04–2.68) 2.00 (1.82–2.18) 2.36 (1.71–3.01)
Model 2 0.73 (0.47–0.99) 1.85 (0.85–2.86) 0.34 (0.01– 0.66) 1.29 (1.02–1.55) 1.71 (1.62–1.79) 1.99 (1.74–2.25) 2.40 (2.08–2.72) 1.85 (1.67–2.04) 2.13 (1.48–2.78)
Model 3 0.68 (0.42–0.94) 1.44 (0.45–2.43) NA 1.33 (1.05–1.60) 1.66 (1.58–1.75) 1.99 (1.74–2.24) 2.42 (2.10–2.74) 1.80 (1.60–1.99) 2.02 (1.36–2.67)
Model 4 0.79 (0.48–1.09) 1.47 (0.48–2.46) NA 1.30 (1.03–1.57) 1.66 (1.57–1.75) 1.99 (1.74–2.24) 2.41 (2.10–2.73) 1.70 (1.48–1.93) 2.03 (1.37–2.69)
Model 5 0.77 (0.45–1.08) 1.48 (0.47–2.49) NA 1.33 (1.05–1.61) 1.65 (1.55–1.75) 2.02 (1.76–2.28) 2.43 (2.11–2.75) 1.79 (1.55–2.03) 2.05 (1.39–2.72)
CI, conﬁdence interval; CIC, Complesso Integrato Columbus; CRISIS, Chronic Renal Insufﬁciency Standards Implementation Study; eGFR, estimated glomerular ﬁltration rate; LACKABO, London Arterial Calciﬁcation, Kidney and Bone
Outcomes; MAURO, multiple intervention and audit in renal diseases to optimize care; NA, not applicable; PECERA, Proyecto de Estudio Colaborativo En pacientes con insuﬁciencia Renal Avanzada; PIRP, prevention of renal
insufﬁciency progression; PRD, primary renal disease; TABLE, target blood pressure levels in CKD.
Model 1, crude (*adjusted for baseline eGFR by use of random intercept); Model 2, age and sex adjusted; Model 3, 2 þ PRD; Model 4, 3 þ comorbidities (diabetes, hypertension, and obesity); Model 5, 4 þ smoking.
Table 6 | Mean annual adjusted eGFR decline (ml/min per 1.73 m2; 95% CI) by subgroup
Country Belgium Cyprus Italy Spain UK
Study Ghent Nicosia CICa MAURO PIRP TABLE PECERA CRISIS LACKABO
#65 yr 0.88 (0.40–1.37) 1.85 (þ1.10– 4.80) NA 1.44 (1.04–1.85) 1.88 (1.69–2.06) 2.32 (1.92–2.73) 3.02 (2.43–3.60) 2.17 (1.84–2.49) 2.05 (1.18–2.91)
>65 yr 0.84 (0.28–1.39) 1.20 (þ1.92– 4.33) NA 1.40 (0.86–1.94) 1.50 (1.07–1.58) 1.94 (1.42–2.46) 2.21 (1.52–2.90) 1.76 (1.37–2.14) 2.48 (1.15–3.80)
Female 0.26 (þ0.10– 0.61) 1.55 (þ0.29– 3.39) þ0.12 (þ0.62– 0.38) 0.78 (0.36–1.20) 1.07 (0.92–1.22) 1.41 (1.02–1.80) 1.75 (1.27–2.23) 0.89 (0.56–1.21) 0.10 (þ1.03– 1.23)
Male 1.00 (0.58–1.42) 1.49 (þ0.67– 3.64) 0.57 (þ0.08– 1.22) 1.21 (0.69–1.74) 1.23 (1.05–1.40) 1.92 (1.43–2.42) 2.29 (1.69–2.89) 1.03 (0.66–1.39) 2.47 (1.11–3.84)
Non-DM 0.60 (0.27–0.93) 1.29 (þ0.20– 2.78) NA 0.84 (0.51–1.17) 1.03 (0.91–1.15) 1.65 (1.36–2.44) 2.06 (1.67–2.44) 0.97 (0.70–1.24) 1.54 (0.81–2.27)
DM 1.07 (0.55–1.58) 1.63 (þ0.32– 3.61) NA 1.37 (0.82–1.92) 1.40 (1.20–1.59) 1.78 (1.22–2.34) 2.08 (1.46–2.69) 0.94 (0.54–1.33) 2.07 (0.40–3.74)
þeGFR, indicates increase instead of decline; CI, conﬁdence interval; CIC, Complesso Integrato Columbus; CRISIS, Chronic Renal Insufﬁciency Standards Implementation Study; DM, diabetes mellitus; eGFR, estimated glomerular
ﬁltration rate; LACKABO, London Arterial Calciﬁcation, Kidney and Bone Outcomes; MAURO, multiple intervention and audit in renal diseases to optimize care; NA, not applicable; PECERA, Proyecto de Estudio Colaborativo En
pacientes con insuﬁciencia Renal Avanzada; PIRP, prevention of renal insufﬁciency progression; PRD, primary renal disease; TABLE, target blood pressure levels in CKD.
aResults for the CIC cohort are presented as crude values. All other results are adjusted for: baseline eGFR, age, sex, PRD, diabetes mellitus, hypertension, obesity and smoking status.
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as it is impossible to fully correct for baseline eGFR in this
situation.
The PIRP, CRISIS, and LACKABO cohorts had identical
exclusion criteria and excluded patients solely on the basis of
RRT or with acute kidney injury. Across these cohorts, the
adjusted eGFR decline varied slightly from 1.65 (95% CI, 1.55
to 1.75) in the PIRP cohort to 2.05 (95% CI, 1.39 to 2.72) ml/
min per 1.73m2 per year in the LACKABO cohort. In
contrast, there was a signiﬁcant variation in the adjusted
mortality rate, from 0.22 (95% CI, 0.11 to 0.43) in the
LACKABO cohort to 1.30 (95% CI, 1.13 to 1.49) in the
CRISIS cohort.
A recently published study by Bello et al.26 showed large
differences in CKD care and policy across European coun-
tries, such as the number of nephrologists, the existence/
absence of referral guidelines, and in the provider payments
for CKD care. As the cohorts are included from all over
Europe, it is likely that inter-regional differences have
contributed to the observed differences in CKD outcomes. We
will discuss the possible inﬂuence of such factors starting with
the regional population health, then the selection of patients
who received specialist nephrology care, and ﬁnally the in-
ﬂuence of the CKD management by the nephrologist.
Regional population health
In RRT patients, 26% of regional variation in mortality is
explained by differences in general population mortality.27
Hence, it is likely that variations in regional population
health may also contribute to differences in both eGFR decline
and mortality across CKD cohorts. We tried to reduce this
inﬂuence by adjusting for the most important comorbidities,
diabetes mellitus, hypertension, and obesity. As population
health is determined by many more factors, it may still
inﬂuence the results. In the 2 English cohorts, for example,
the observed differences in mortality risk seemed to reﬂect
previously reported differences in population health.28,29 The
adjusted mortality HR varied from 0.22 (95% CI, 0.11 to
0.43) in the London-based LACKABO study to 1.30 (95% CI,
1.13 to 1.49) in the CRISIS study. The CRISIS cohort is set in
the northwest of England, where social deprivation and
mortality are reportedly relatively high.28 The population of
London is ethnically diverse,30 which corresponds to the high
percentage of ethnic minorities (28%) in the LACKABO
cohort. Previously, Barbour et al.31 reported rapid eGFR
decline rates and low mortality in Asian CKD patients
compared to Caucasian CKD patients. Similarly, Dreyer
et al.32 reported faster eGFR decline in diabetic CKD patients
in South Asian and black ethnic groups than in whites. Hence,
it is possible that both the relatively fast eGFR decline and the
low mortality risk in the LACKABO cohort can be in part
contributed to the high percentage of ethnic minorities.
Access to specialist care
Apart from the selection of CKD patients through inclusion
and exclusion criteria, there was an additional selection of1438patients determined by the organization of the regional health
care system. Differences in access to specialist care will likely
inﬂuence the overall health of the CKD population seen in
outpatient nephrology clinics. In Belgium, the health system
allows open access to specialist care (i.e., patients do not need
a referral from a general practitioner).33 Without a general
practitioner’s referral, there is no selection based on rate of
eGFR decline or at-risk patients, and thus more healthy pa-
tients have access to a specialist’s care. This may have
contributed to the slow eGFR decline and low mortality we
observed in the Belgian study. A slow eGFR decline was seen
not only in the Belgian cohort but also in the other cohorts
with open access (i.e., the Cypriot,34 the CIC, and the
MAURO cohorts).
In Italy, Spain, and England, access to specialists’ care is in
principle limited to patients with a referral from their general
practitioner (i.e., the gatekeeper system).35–37 Nonetheless, in
2005 in Italy, 56.8% of all visits made by specialists were
privately paid by patients, although the proportion made
among different specialties was quite variable.36 Speciﬁc data
for specialists’ care in nephrology were not available. Among
the Italian cohorts in the present study, PIRP and
TABLE included only referred patients, whereas MAURO and
CIC also allowed open access to patients. This might have
contributed to the large variability in eGFR decline and
mortality observed across these Italian cohorts.
In the English and Spanish cohorts, patients did need a
referral to visit a nephrology specialist at an outpatient clinic,
and both countries had referral criteria in place during (part
of) the study enrollment period. In the United Kingdom, the
Royal College of Physicians published referral criteria for
CKD patients in 2005,38 and in Spain, the Spanish Society of
Nephrology published these criteria in 2008.39 Overall, the
national referral criteria are quite similar, and CKD patients
with eGFR below 30 ml/min per 1.73 m2 required referrals in
both countries. This may perhaps partly explains the relative
small variations in eGFR decline across the Spanish and En-
glish populations.
CKD management
CKD management can inﬂuence the rate of eGFR decline and
mortality risk.7,40 For instance, multiple studies have shown
that treatment with ACEi and ARB therapy can reduce pro-
teinuria, lower blood pressure, and slow CKD progres-
sion.41,42 Consequently, the observed differences in baseline
ACEi and ARB use, ranging from 25% to 75%, may have
contributed to the differences in CKD progression. Impor-
tantly, we chose to focus on the results adjusted for everything
but ACEi and ARB use, as treatment differences reﬂect cur-
rent regional practice. Moreover, CKD management, for
example, through ACEi and ARB medication is in the causal
pathway between the baseline cohort eGFR and CKD out-
comes. We only analyzed this to assess to what extent dif-
ferences in CKD outcomes were mediated through ACEi and
ARB use. The adjustment for ACEi and ARB use in our model
slightly reduced eGFR decline in only 4 studies, indicatingKidney International (2018) 93, 1432–1441
K Brück et al.: Progression and mortality in CKD c l i n i ca l i nves t iga t ionthat treatment differences with ACEi and ARB medication did
not explain the variations in CKD progression.
Strengths and limitations
Our study has multiple strengths and limitations. The main
strength of our study is the use of a sophisticated joint model
analysis, which enabled us to account for the measurement
error of eGFR. This is conﬁrmed by the robustness of results
in the sensitivity analyses, where we increased the minimum
from 2 to 3 creatinine measurements. Moreover, the joint
model corrects for the association between change in eGFR
and mortality and the potential bias related to this associa-
tion. One drawback of the model is the requirement of at least
2 creatinine measurements, thus excluding patients who
dropped out early, which could have led to a selection bias.
Other strengths of our study include the big sample size and
adjustments for important factors including age, sex, baseline
eGFR, albuminuria, PRD, and presence of diabetes, hyper-
tension, and obesity, and smoking status and medication use.
Although we did correct for baseline albuminuria, we did not
assess change in albuminuria as only few cohorts provided
repeated measurements of albuminuria. A limitation of any
observational study is that no causative conclusions from the
observed associations can be made. In addition, the results are
based on CKD patients in nephrology outpatient clinics, and
consequently, the results are not generalizable to undiagnosed
CKD patients or CKD patients in primary care. Moreover,
nephrology practice may vary per clinic and region, and
therefore, the results should not be extrapolated to a national
level. Finally, we did not collect ethnicity data from all co-
horts, and differences in ethnicity might have inﬂuenced the
observed CKD outcomes.
Conclusion
We observed clinically relevant variations in outcomes in
CKD patients from outpatient nephrology clinics across Eu-
ropean regions. Apart from the very slow decline in the
Belgian cohort, adjusted mean annual eGFR decline varied
only slightly across other cohorts. In contrast, we did ﬁnd
marked differences in mortality risk across the cohorts. This
paper is a ﬁrst step in identifying regional health care systems
effective in preventing CKD progression and improving sur-
vival by monitoring CKD progression and mortality in CKD
patients attending outpatient nephrology clinics across Eu-
ropean regions.
METHODS
Search strategy
We performed a search of published studies in PubMed to identify
studies which could contribute data for CKD progression in patients
from outpatient nephrology clinics and were published between
2000 and the end of 2012. The full search terms are presented in
Supplementary Appendix S1.
Study selection
Studies were included when carried out in CKD patients not
undergoing RRT in an outpatient nephrology clinic within EuropeKidney International (2018) 93, 1432–1441and when creatinine follow-up measurements were available. We
excluded studies with a sample size of less than 100 participants,
studies not using eGFR based on serum creatinine equations,
intervention trials, and review articles. No language restrictions
were applied. The search was done by 1 investigator (KB). Any
study that was judged relevant on the basis of its title was retrieved
in abstract form, and if relevant, in full-text form. When eligibility
was unclear this was resolved by discussion with another investi-
gator (VSS). We extended our search by reviewing references from
retrieved articles and review articles. Further studies and unpub-
lished data were sought by communication with collaborators,
nephrologists, and country representatives. Additionally, study
groups were encouraged to join the European CKD Burden Con-
sortium through a call in the newsletter of the 2012 European Renal
Association – European Dialysis and Transplant Association (ERA-
EDTA) congress in Paris.
Data extraction
Eligible study groups that agreed to participate were asked to send a
limited anonymized dataset with individual patient data including
baseline characteristics and follow-up measurement of serum
creatinine and (if available) albuminuria/proteinuria measurements.
We excluded in-patient serum creatinine measurements and mea-
surements after the start of RRT.
Diabetes mellitus was deﬁned according to the 2006 World
Health Organization criteria,43 and hypertension was deﬁned as the
use of antihypertensive medication or a systolic blood pressure
of $140 mm HG or diastolic blood pressure of $90 mm Hg.
Obesity was deﬁned as a body mass index $30 kg/m2. We recoded
the received PRD into 8 main categories based on comparability of
the individual cohort deﬁnitions.
Study cohorts provided information for the creatinine assay
method used, the use of IDMS calibration, and if any changes in
methods occurred during follow-up. None of the laboratories
changed the creatinine assay method during the follow-up period.
Serum creatinine results from non–IDMS-calibrated creatinine
measurement methods were reduced by 5% as suggested by Levey
et al.44 We used the CKD-EPI equation to estimate GFR.45 Baseline
albuminuria was divided into normoalbuminuria (albumin creati-
nine ratio <30 mg/g, or protein creatinine ratio <150 mg/g, or
proteinuria <150 mg/24 h), microalbuminuria (albumin creatinine
ratio 30 to 300 mg/g, protein creatinine ratio 150 to 500 mg/g, or
proteinuria 150 to 500 mg/24 h) or macroalbuminuria (albumin
creatinine ratio >300 mg/g, protein creatinine ratio >500mg/g, or
proteinuria >500 mg/24 h).7,46
Statistical analysis
We performed a joint model analysis combining a longitudinal
(linear mixed) model with a Weibull survival model.9 By combining
the longitudinal model with the survival model, the joint model
accounted for mortality and reduced bias resulting from measure-
ment error in eGFR.11 The latter method leads to an estimation of
the underlying error-free eGFR.
The longitudinal part of the model estimates the rate of change in
eGFR over time, taking into account the varying number and spacing
of eGFR measurements as well as the variable follow-up duration for
each subject. In the survival model, death was the outcome, and
patients were censored when lost to follow-up or at initiation of RRT.
We added a penalty for initiation of RRT by imputing an eGFR of 5
ml/min per 1.73 m2 at the day of RRT initiation. Time was deﬁned in
years since the ﬁrst serum creatinine measured in outpatient1439
c l i n i ca l i nves t iga t i on K Brück et al.: Progression and mortality in CKDnephrology care. The Italian PIRP cohort was chosen as the reference
category based on population size. We determined the mean eGFR
change in ml/min per 1.73m2 per year and the HR for mortality. To
improve comparability of study cohorts, all studies were analyzed
together, but the results are presented by study. The analysis was
performed “crude” including only the inherent adjustment for
baseline eGFR (model 1) and adjusted for the following potential
confounders: age, sex (model 2), plus PRD (model 3), plus diabetic,
hypertensive, and obesity status (model 4), plus smoking (model 5).
To evaluate the impact of ACEi and ARB use in the causal pathway
between baseline cohort eGFR and CKD outcomes, we added this
variable into the model (model 6). All potential confounders were
entered in the survival submodel as covariates and in the longitu-
dinal model as both covariate main effects and interactions with
time. In addition, eGFR decline was also presented by, a priori
deﬁned, subgroups based on age group (65 years of age), sex, and
presence of diabetes mellitus. In Supplementary Appendix S1, a
more extensive explanation of the joint model can be found,
including 2 tables with the parameters of both the longitudinal and
the survival models.
Presence of albuminuria is associated with CKD progression,7
but baseline albuminuria data were only partly available. Because
we could not fully correct for baseline albuminuria in the total
population, we restricted the main analysis to subjects with CKD
stages 3 to 5 (i.e., eGFR <60 ml/min per 1.73m2), as subjects with
CKD stages 1 and 2 will likely have some degree of albuminuria.7
Moreover, this restriction improved comparability of the CKD
cohorts as they differed with regard to percentage of patients per
CKD stage. In total, we performed 4 sensitivity analyses: (i) only
subjects with available albuminuria data, to adjust for baseline
albuminuria; (ii) subjects with at least 3 creatinine measurements
(in the main analysis the required minimum was 2), which is
recommended by Kidney Disease: Improving Global Outcomes to
reduce the inﬂuence of measurement error in eGFR7; (iii) the joint
model was run for the 9 individual studies separately (as compared
to the main analyses in which all studies were included in 1 model),
to show the eGFR decline by cohort independent of the decline
from other cohorts; and (iv) the model without a penalty for RRT,
using only the original, last eGFR value. The results of the sensi-
tivity analyses are shown in Supplementary Table S4, S5, S6, and S7.
All analyses were performed in Stata/SE version 14 software (Col-
lege Station, TX). The “stjm” command was used for the joint
model analysis.9
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